Ketamine review explores gene regulation mechanisms, mostly in preclinical studies
The review describes molecular changes linked to ketamine, while limited human evidence leaves their relevance to depression treatment uncertain.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The review suggests that ketamine may influence gene regulation through several molecular pathways relevant to depression research. Most evidence came from preclinical studies, and the human data were limited. The findings offer possible explanations for ketamine's effects, but they do not establish that these mechanisms account for symptom improvement in people.
The authors highlight limited human data and uncertain clinical relevance. The abstract provides no pooled estimate of symptom improvement, so this abstract-based summary cannot quantify treatment benefit or establish which mechanism matters most.
Changes in gene activity
The review described changes in how genes are regulated, including histone modifications and non-coding RNAs. Some studies reported restored expression of genes involved in synaptic signaling and stress, including brain-derived neurotrophic factor.
Why the setting matters
The review draws mainly on preclinical work, so its molecular findings cannot be assumed to describe what happens in patients. The authors call for studies connecting these mechanisms with clinically relevant outcomes in humans.
The original publication
The epigenetic mechanisms of ketamine in the treatment of depression: a systematic review.
Leccisotti I, Moretti MC, Altamura M et al.
Epigenomics · 2025
- PubMed ID
- 41201073
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.